Presentation is loading. Please wait.

Presentation is loading. Please wait.

The Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy  Arya Amini, BA, Arlene.

Published byRenée Damours Modified over 5 years ago

Similar presentations

Presentation on theme: "The Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy  Arya Amini, BA, Arlene."— Presentation transcript:

1 The Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy  Arya Amini, BA, Arlene M. Correa, PhD, Ritsuko Komaki, MD, Joe Y. Chang, MD, PhD, Anne S. Tsao, MD, Jack A. Roth, MD, Stephen G. Swisher, MD, David C. Rice, MD, Ara A. Vaporciyan, MD, Steven H. Lin, MD, PhD  The Annals of Thoracic Surgery  Volume 94, Issue 3, Pages (September 2012) DOI: /j.athoracsur Copyright © 2012 The Society of Thoracic Surgeons Terms and Conditions

2 Fig 1 Kaplan-Meier curves illustrating (A) cumulative locoregional (LR)-free probability, (B) cumulative distant metastasis (DM)-free recurrence, and (C) cumulative overall survival (OS) with postoperative chemotherapy (chemo) versus without postoperative chemotherapy. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2012 The Society of Thoracic Surgeons Terms and Conditions

Download ppt "The Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy  Arya Amini, BA, Arlene."

Similar presentations

Differential Response to Preoperative Chemoradiation and Surgery in Esophageal Adenocarcinomas Based on Presence of Barrett's Esophagus and Symptomatic.

Differential Response to Preoperative Chemoradiation and Surgery in Esophageal Adenocarcinomas Based on Presence of Barrett's Esophagus and Symptomatic.
Advantage of Induction Chemoradiotherapy for Lung Cancer in Securing Cancer-Free Bronchial Margin  Hiroki Sato, MD, Shinichi Toyooka, MD, PhD, Junichi.

Advantage of Induction Chemoradiotherapy for Lung Cancer in Securing Cancer-Free Bronchial Margin  Hiroki Sato, MD, Shinichi Toyooka, MD, PhD, Junichi.
The evolution of treatment outcomes for resected stage IIIA non–small cell lung cancer over 16 years at a single institution  Linda W. Martin, MD, Arlene.

The evolution of treatment outcomes for resected stage IIIA non–small cell lung cancer over 16 years at a single institution  Linda W. Martin, MD, Arlene.
Elizabeth A. David, MD, David T

Elizabeth A. David, MD, David T
Outcomes of Major Lung Resection After Induction Therapy for Non-Small Cell Lung Cancer in Elderly Patients  Chi-Fu Jeffrey Yang, MD, Nicholas R. Mayne,

Outcomes of Major Lung Resection After Induction Therapy for Non-Small Cell Lung Cancer in Elderly Patients  Chi-Fu Jeffrey Yang, MD, Nicholas R. Mayne,
Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes  Meng S. Shao, MD, Andrew T. Wong, MD,

Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes  Meng S. Shao, MD, Andrew T. Wong, MD,
Treating Constrictive Pericarditis in a Chinese Single-Center Study: A Five-Year Experience  Yiyun Lin, MD, Mi Zhou, MMS, Jian Xiao, MD, Bin Wang, MD,

Treating Constrictive Pericarditis in a Chinese Single-Center Study: A Five-Year Experience  Yiyun Lin, MD, Mi Zhou, MMS, Jian Xiao, MD, Bin Wang, MD,
Thomas J. Birdas, MD, Richard P. M

Thomas J. Birdas, MD, Richard P. M
Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F
Utility of PET, CT, and EUS to Identify Pathologic Responders in Esophageal Cancer  Stephen G. Swisher, MD, Mary Maish, MD, Jeremy J. Erasmus, MD, Arlene.

Utility of PET, CT, and EUS to Identify Pathologic Responders in Esophageal Cancer  Stephen G. Swisher, MD, Mary Maish, MD, Jeremy J. Erasmus, MD, Arlene.
Joshua E. Rosen, BASc, Hari B

Joshua E. Rosen, BASc, Hari B
Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis

Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis
Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer  Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.

Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer  Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.
Puja Gaur, MD, Wayne L. Hofstetter, MD, B

Puja Gaur, MD, Wayne L. Hofstetter, MD, B
Matthew D. Taylor, MD, Alykhan S. Nagji, MD, Castigliano M

Matthew D. Taylor, MD, Alykhan S. Nagji, MD, Castigliano M
Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 
Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non–Small Cell Lung Cancer: A Phase II Clinical Trial 

Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non–Small Cell Lung Cancer: A Phase II Clinical Trial 
Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population  Edmund S. Kassis, MD, Ara A. Vaporciyan,

Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population  Edmund S. Kassis, MD, Ara A. Vaporciyan,
Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.

Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.
Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy  Apar Pataer, MD, PhD, Neda Kalhor,

Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy  Apar Pataer, MD, PhD, Neda Kalhor,

Similar presentations

Ads by Google